FAP-targeted PET/NIR in Lung Malignant Tumors
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorPeking University People's Hospital
About this trial
Single center, prospective, diagnostic study. Patients with stage II-IIIB resectable NSCLC diagnosed by pathology were included. After receiving standard neoadjuvant therapy (chemotherapy/immunotherapy/combination therapy), FAPI-PET/CT and fluorescence imaging were performed one week before surgery. During the surgery, a near-infrared fluorescence navigation system was used to locate the tumor lesion. After surgery, the tumor bed range was determined by pathological gold standards (HE staining+immunohistochemistry), and the predictive efficacy and localization accuracy of FAPI-PET/fluorescence were compared and analyzed.
Eligibility criteria
Qualifiers
Age between 18 and 70 years old;
Have complete clinical and imaging data;
Prior to neoadjuvant therapy, the biopsy pathology showed lung cancer;
Able to retain sufficient tumor tissue for testing and research;
Disqualifiers
Previously combined with other malignant tumors or received other anti-tumor treatments;
Failure to collect sufficient tumor tissue for testing and research;
The duration of neoadjuvant therapy is less than 3 cycles;
The dynamic scanning image quality of multimodal probe PET cannot meet the analysis standards or is missing;
Trial design
Treatments tested in this trial
- PET/CT scans
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov